Galectin Therapeutics (NASDAQ: GALT)

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Find a broker to begin trading GALT now

Company Name Galectin Therapeutics
Market/Symbol NASDAQ: GALT
Recent Price
Market Cap $64.74M
Avg. Daily Vol. (3m) 492,152
Price/Book N/A
Price/Cash Flow N/A
As of Mar. 22, 2017
*Source: QuoteMedia

Begin trading GALT

 Find Broker

Recent Company Videos

Galectin Therapeutics: Mutliple Near-Term Phase 2 Trials for Fibrosis

Apr. 27, 2015

Galectin Therapeutics (NASDAQ: GALT) - Presentation and Q/A session recorded at the April 2015 RedChip Global Online CEO Conference. Galectin ...

Galectin Therapeutics Latest News

Ask the CEO

Historical SEC Filings

Date Form Title
Mar 14, 2017 8-K 8-K - Current report
Feb 17, 2017 8-K 8-K - Current report
Feb 07, 2017 8-K 8-K - Current report
Feb 02, 2017 8-K 8-K - Current report
Feb 01, 2017 8-K 8-K - Current report
Jan 18, 2017 SC 13D SC 13D - General statement of acquisition of beneficial ownership
Jan 06, 2017 D D - Notice of Exempt Offering of Securities
Dec 29, 2016 8-K 8-K - Current report
Dec 20, 2016 8-K 8-K - Current report
Nov 10, 2016 8-K 8-K - Current report

RedChip Direct Investment Opportunities For Private and Public Companies

Receive GALT Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market